Why the study?
Does dipeptidyl peptidase IV inhibition improve pulmonary vascular and right ventricular remodeling in experimental pulmonary hypertension?
Does dipeptidyl peptidase IV inhibition improve pulmonary vascular and right ventricular remodeling in experimental pulmonary hypertension?
Dipeptidyl peptidase IV inhibition protects against pulmonary vascular and right ventricular remodeling in experimental pulmonary hypertension, a mechanism mediated by GLP-1 and the inhibition of endothelial-to-mesenchymal transition.
Answers are grounded in this paper and cite their sources.
Supports GLP-1 pathway in experimental PH remodeling; leaves open translation to human therapy.
Our data suggest that GLP-1 mediated the protective effects of DPP-4i on pulmonary vascular and RV remodeling in experimental PH, which may be attributed to the inhibitory effect on EndMT.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: